Skip to main content
Joseph Tauber, MD, Ophthalmology, Kansas City, MO

JosephTauberMD

Ophthalmology Kansas City, MO

Cornea & External Disease, Refractive Surgery, Retinal Disease, Uveitis

Owner, Tauber Eye Center

Dr. Tauber is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Tauber's full profile

Already have an account?

Summary

  • Dr. Joseph Tauber is an ophthalmologist in Kansas City, MO. He specializes in cornea & external disease, refractive surgery and uveitis and is experienced in sjogren's syndrome, cataract surgery, corneal transplant surgery. He is also Chief Medical Officer for Brightstar Therapeutics and of Vital Tears.

Education & Training

  • Massachusetts Eye and Ear Infirmary/Harvard Medical School
    Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolFellowship, Cornea, External Diseases, and Refractive Surgery, 1988 - 1989
  • Massachusetts Eye and Ear Infirmary/Harvard Medical School
    Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolResidency, Ophthalmology, 1987 - 1989
  • Massachusetts Eye and Ear Infirmary/Harvard Medical School
    Massachusetts Eye and Ear Infirmary/Harvard Medical SchoolFellowship, Ocular Immunology/Uveitis, 1987 - 1988
  • Tufts Medical Center
    Tufts Medical CenterResidency, Ophthalmology, 1984 - 1987
  • Icahn School of Medicine at Mount Sinai (Beth Israel)
    Icahn School of Medicine at Mount Sinai (Beth Israel)Internship, Internal Medicine, 1983 - 1984
  • Northwestern Medical Center
    Northwestern Medical Center1982 - 1983
  • Harvard Medical School
    Harvard Medical SchoolClass of 1982
  • Union College
    Union CollegeBS, Biology and Chemistry, Summa Cum Laude, 1978

Certifications & Licensure

  • MO State Medical License
    MO State Medical License 1989 - 2025
  • KS State Medical License
    KS State Medical License 1997 - 2024
  • American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

  • Member, Cornea Subcommittee American Academy of Ophthalmology Program Committee 2002-2006, 2006
  • American Academy of Ophthalmology Achievement Award 2005
  • National Eye Institute Individual NRSA Award (EY06052) Massachusetts Eye & Ear Infirmary, 1987-1989, 1989
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Refractive Outcomes Following Excimer Laser Photorefractive Keratectomy for Myopia Using Two Different VISX Excimer Lasers.  
    Cable M, Matta C, Piebenga L, Polepalle S, Steward C, Tauber J, Investigative Ophthalmology Visual Science 40 (4): S106
  • Safety and Efficacy of Nedocromil Sodium Ophthalmic Solution 25 BID in Patients with Ocular Itch Associated With Allergic Conjunctivitis.  
    Tauber J, Alocril Community Ocular Allergy Trial Study Group, Investigative Ophthalmology Visual Science 42(4) S910
  • Efficacy and Safety of Combination Therapy with Brimonidine 0.2% and Latanoprost 0.005% Versus Fixed Combination Timolol 0.5%/Dorzolamide 2%  
    Zabriskie N A, Ahmed I K, Cantor L B, Kent A B, Mundorf T, Tauber J, Rubin J M, Hoop J, Investigative Ophthalmology Visual Science 42 (4) S833
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Authored Content

  • Myths and Misconceptions About Autologous Serum for Dry EyeJune 2020

Press Mentions

  • Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual Meeting
    Bausch + Lomb Presents Data from First Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual MeetingApril 25th, 2022
  • VivaVision Biotech Announces Positive Topline Results of VVN001 in the Phase 2 Clinical Study for the Treatment of Dry Eye Disease
    VivaVision Biotech Announces Positive Topline Results of VVN001 in the Phase 2 Clinical Study for the Treatment of Dry Eye DiseaseMarch 23rd, 2022
  • Chutes & Ladders—Novartis Loses 2 Leaders, One to MiroBio, Another to a Video Game Company
    Chutes & Ladders—Novartis Loses 2 Leaders, One to MiroBio, Another to a Video Game CompanySeptember 24th, 2021
  • Join now to see all

Professional Memberships